Study S000740

Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of Oral LUM-201 as an Adjunct to Oral Semaglutide for Improving Physical Function in Older Adults With Obesity

ClinicalTrials.gov record

Registration

Registration: NCT07754045
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: NOT_YET_RECRUITING
Enrollment: 202
Start: 2027-02-15
Primary completion: 2028-02-15
Lead sponsor: Lumos Pharma
Conditions: Obesity & Overweight
Interventions: DRUG:LUM-201; DRUG:Placebo; DRUG:Semagludtide
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Proportion of participants with Short Physical Performance Battery (SPPB) score ≤ 7 at Week 26. [From Day 1 to week 26]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.